Drug intelligence / Profile preview

ELV001

Development stage: Phase 2
Lead developer: Elevara Medicines
Modality: Small Molecules
Administration: Oral

Overview

ELV001 is a first-in-class oral small molecule CDK4/6 inhibitor developed by Elevara Medicines for the treatment of rheumatoid arthritis. The drug was initially researched by Teijin Pharma for over a decade before Elevara Medicines acquired exclusive global rights for its development, commercialization, and manufacturing. Having successfully completed Phase 1 trials, ELV001 is currently advancing into Phase 2 clinical trials for rheumatoid arthritis.

Targets

CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on ELV001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELV001.

Explore the full profile